by treadwell | Aug 27, 2020 | Uncategorized
Treadwell Announces Initiation of Expansion Cohorts in Ongoing Phase 1 Study of Oral TTK Inhibitor, CFI-402257, in Patients with Breast Cancer and Additional Solid...
by treadwell | Aug 12, 2020 | Uncategorized
Treadwell Announces Initiation of Phase 2 Study of CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer (TNBC):...
Recent Comments